Podcasts about Cart

Andrew Yee, MD Multiple myeloma can feel unfamiliar and overwhelming at first, but today's advances tell a much brighter story. In this episode, Dr. Andrew Yee of Massachusetts General Hospital explains what myeloma is, how it's diagnosed, and why new treatment options, from four-drug regimens to CAR T-cell therapy and bispecific antibodies, are transforming patient outcomes. With enthusiasm and relatable analogies, he highlights how patients may progress from periods of significant challenges to reaching a level of stability and well‑being that allows them to live fully. This conversation offers clarity, confidence, and real optimism for anyone navigating myeloma. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Multiple myeloma Amyloidosis Autologous stem cell transplantation CAR T-cell therapy Immunotherapy fact sheet Clinical Trial Support Center Additional Blood Cancer United Support Resources: Information Specialists Financial support Online Chat Free Nutrition Consultations Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by AbbVie Inc.; Bristol Myers Squibb; Genentech, A Member of the Roche Group; GSK plc.; Johnson & Johnson. The post Facing Multiple Myeloma: A Guide to Choices, Care, and Confidence first appeared on The Bloodline with Blood Cancer United Podcast.

The price you see online might not be the real price. A new investigation found that Instacart was quietly running pricing experiments—charging different customers different prices for the same groceries at the same time. This week, Paul and Goldy talk with Groundwork Collaborative Executive Director Lindsay Owens about how companies are using AI and massive data sets to run experiments on consumers—testing exactly how much each of us is willing to pay. And if every shopper sees a different price, one big question follows: Do markets still work the way economists say they do? Lindsay Owens is the Executive Director of the economic think tank Groundwork Collaborative and author of the forthcoming book, GOUGED: The End of a Fair Price in America. Further Reading:  Same Cart, Different Price: Instacart's Price Experiments Cost Families at Checkout We Had 400 People Shop For Groceries. What We Found Will Shock You. Gouged: The End of a Fair Price--and What That Means for Your Wallet Social Media: BlueSky: @lindsayowens.bsky.social Instagram: @lindsayowensphd TikTok: @lindsayowensphd Twitter: @owenslindsay1 BlueSky: @groundwork.bsky.social Twitter: @Groundwork Organizations developing policy on surveillence pricing:  American Economic Liberties Project Economic Security Project Tech Equity Consumer Reports  More Perfect Union Website: http://pitchforkeconomics.com Facebook: Pitchfork Economics Podcast Bluesky: @pitchforkeconomics.bsky.social Instagram: @pitchforkeconomics Threads: pitchforkeconomics TikTok: @pitchfork_econ YouTube: @pitchforkeconomics LinkedIn: ⁠Pitchfork Economics⁠ Twitter: @PitchforkEcon, @NickHanauer Substack: The Pitch

Guest: Dr. Daniel Peeper is a Professor in Functional Oncogenomics at VU University Amsterdam, heading the Department of Molecular Oncology & Immunology and chairing the Research Faculty Council Board at the Netherlands Cancer Institute. His lab employs function-based, genome-wide screens and other advanced technologies to develop concepts for rational combinatorial cancer treatment, targeting both cancer and immune cells more effectively. Featured Products and Resources: Obtain highly purified cells in a single step with the Easy 250 EasySep Magnet. Download a free wallchart on the production of CAR T cells. The Immunology Science Round Up Genomic Insights into EBV – Researchers used genome sequencing data to identify genetic and lifestyle factors linked to control of persistent Epstein–Barr virus (EBV) infection and its association with autoimmune diseases. Cholinergic Control of B Cells – Acetylcholine signaling in germinal center B cells helps regulate their selection and differentiation to shape high-affinity antibody responses. Targeting Persistent HIV Clones – Persistent HIV reservoir T cell clones resist immune clearance but remain vulnerable to sustained cytotoxic T cell pressure. T Cell Engagers in Autoimmunity – CD19×CD3 and BCMA×CD3 T cell engagers improved disease outcomes in patients with treatment-refractory antisynthetase syndrome and systemic sclerosis. Image courtesy of Daniel Peeper Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

O Cartão Village é da bandeira Visa, emitido pela CREDZ O Cartão Village pode ser utilizado no Brasil, no exterior e em compras online.O Cartão Village é um meio de pagamento que pode ser usado em estabelecimentos físicos e plataformas digitais, oferecendo aceitação ampla para compras em diversas categorias. Emitido pela CREDZ, o cartão possui a bandeira Visa, o que possibilita sua utilização em uma rede global de lojas, restaurantes e serviços. Além disso, ele é compatível com compras realizadas por meio de aplicativos e sites, facilitando pagamentos online. Solicite o seu cartão de créditohttps://tinyurl.com/39n45vd4CÓDIGOS DE INDICAÇÃO CARTÃO DE CRÉDITOhttps://bit.ly/3RuEZ21GRUPO GRATUITO NO WHATSAPPhttps://tinyurl.com/5n79dtkmLivros sobre Educação Financeira https://amzn.to/47uuEY2Nosso site https://girofinanceiro.com.br/Canal do Youtube https://tinyurl.com/43jux7mr

Alan interviews Todd Hanson. Todd Hanson is an avid deer hunter - who decided to design an improved deer cart. He invented an innovative deer cart that easily carries game and gear, but also installs without unloading to the hitch hauler on the back of a vehicle. His Compass Cart carriers gear of all types over rough terrain. Make sure to subscribe to the podcast at Apple Podcasts, or wherever you get your podcasts, so you won't miss a single episode. website:  www.CompassCarts.com

Medical researchers say New Zealanders are missing out on a transformative cancer treatment that's been proven to make a difference. It's called CAR T-cell therapy. As it stands, Kiwis have to travel thousands of kilometres overseas to receive this treament, which in and of itself is complex and costly. The Malaghan Institute of Medical Research is spearheading an awareness campaign about CAR T-cell therapy this month, and clinical director Professor Robert Weinkove joins me now to discuss it.

[Patrocinado] Com mais de 70 anos de história, a JBS garante qualidade à mesa e alimenta um futuro melhor. Saiba mais em: https://www.jbs.com.br/O presidente Donald Trump disse a um grupo de líderes da América Latina que eles precisam trabalhar com os Estados Unidos para combater cartéis de tráfico de drogas enquanto busca reforçar a liderança americana na região.

Pour écouter mon podcast Choses à Savoir:Apple Podcast:https://podcasts.apple.com/fr/podcast/choses-%C3%A0-savoir-culture-g%C3%A9n%C3%A9rale/id1048372492Spotify:https://open.spotify.com/show/3AL8eKPHOUINc6usVSbRo3?si=e794067703c14028----------------------------La Chine bat son record de production de charbon… tout en annonçant une future taxe carbone nationale. Entre impératifs économiques et engagements climatiques, l'équilibre est fragile.Traduction :China breaks its coal production record—just as it pledges a future national carbon tax. A balancing act between growth and climate promises. Hosted on Acast. See acast.com/privacy for more information.

Pour écouter mon podcast Choses à Savoir:Apple Podcast:https://podcasts.apple.com/fr/podcast/choses-%C3%A0-savoir-culture-g%C3%A9n%C3%A9rale/id1048372492Spotify:https://open.spotify.com/show/3AL8eKPHOUINc6usVSbRo3?si=e794067703c14028----------------------------La Chine bat son record de production de charbon… tout en annonçant une future taxe carbone nationale. Entre impératifs économiques et engagements climatiques, l'équilibre est fragile.Traduction :China breaks its coal production record—just as it pledges a future national carbon tax. A balancing act between growth and climate promises. Hosted on Acast. See acast.com/privacy for more information.

Venha visitar a nossa Loja:https://iconografia-da-historia-3.myshopify.com/?utm_medium=product_shelf&utm_source=youtubeSiga nosso canal de CORTES:https://www.youtube.com/@IconografiadaHistoria-cortesE siga também nosso canal parceiro "CAFÉ E CAOS TV" apresentado pelo nosso querido Fernandão e Agnes Andradehttps://www.youtube.com/@CafeecaostvAJUDE-NOS A MANTER O CANAL ICONOGRAFIA DA HISTÓRIA: Considere apoiar nosso trabalho, participar de sorteios e garantir acesso ao nosso grupo de Whatsapp exclusivo: https://bit.ly/apoiaoidhSe preferir, faz um PIX: https://bit.ly/PIXidhNos acompanhe no Spotify @iconocastSiga ICONOGRAFIA DA HISTÓRIA em todas as redes: https://linktr.ee/iconografiadahistoriaoficialSiga o JOEL PAVIOTTI: https://bit.ly/joelpaviottiApresentação: Joel PaviottiTexto e roteirização: Adriana de PaulaRevisão: Adriana de PaulaCâmera e produção: Fernando ZenerattoEdição: Fernando ZenerattoDireção: Fernando Zeneratto / Joel Paviotti

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of multiple myeloma treatment, focusing on the groundbreaking MajesTEC-3 trial. We had the pleasure of welcoming Dr. Luciano Costa from the University of Alabama, who shared insights on the combination of teclistamab and daratumumab for relapsed refractory multiple myeloma. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: The impressive progression-free survival (PFS) rates observed in the MajesTEC-3 trial, with a PFS of 83.4% at three years. The mechanism of action of teclistamab as a bispecific antibody targeting BCMA and its synergy with daratumumab. Safety profiles, including the management of cytokine release syndrome (CRS) and infection risks, along with the use of IVIG for prophylaxis. The evolving landscape of multiple myeloma therapies, including the role of CAR T-cell therapy versus bispecific antibodies. Join us for this informative discussion that aims to keep healthcare professionals updated on the latest advancements in multiple myeloma treatment. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #MultipleMyeloma, #MajesTEC3, #Teclistamab, #Daratumumab, #BispecificAntibody, #OncBrothers

Coming up, we explore how CAR-T cell therapy is revolutionising personalised cancer treatment. Plus, how NASA's DART mission tested Earth's asteroid defence, what we are learning about the benefits of breastfeeding for mother and baby health, and we delve into the physics behind squeaky shoes... Like this podcast? Please help us by supporting the Naked Scientists

In this episode of the Guns Podcast, Brent Wheat and Roy Huntington take a trip down memory lane—prompted by a literal lightning strike that knocked Roy off the grid. Without the internet, the duo discusses what the shooting world was like before the digital age took over. They explore the days when information came from dog-eared magazines, crusty experts at the gun counter and the anticipation of mail-order catalogs. Is the instant gratification of today's "Add to Cart" culture ruining the experience of firearm ownership? Roy and Brent debate the pros and cons of the digital revolution, arguing that while we are better informed, we may be losing the joy of the "hunt" for gear and knowledge. They also discuss the concept of "sipping vs. gulping" ammunition and why the paralysis of choice might be hindering new shooters. Tune in for a nostalgic look at gun culture, a challenge to take a "digital detox," and some laughs about the way things used to be. Whether you remember ordering from the Sears Wish Book or you've only ever bought gear on Amazon, this episode offers a fresh perspective on slowing down and enjoying the range. Key Takeaways • The transition from 'analog' shooting culture (magazines, catalogs, word-of-mouth) to the digital age. • How the ease of internet purchasing removes the anticipation and appreciation of acquiring new gear. • The concept of 'Potato Chip Information'—consuming vast amounts of data without retaining depth or value. • The loss of institutional knowledge as the 'old guys' at the gun counters disappear. • The difference between 'sipping' ammunition for precision and enjoyment versus 'gulping' through mag dumps. • The benefits of a 'Digital Detox' to reset your attention span and appreciation for the outdoors. • Why owning unique, high-quality firearms is often more satisfying than chasing the latest commodity trends. -- The Guns Podcast is presented by EOTech. EOTECH is the leading manufacturer of electro-optics.  Known for their world-famous holographic weapon sights, EOTECH also provides precision rifle scopes, ruggedized pistol optics, night-vision, thermal, and laser systems to professional and recreational users around the globe.  Visit eotechinc.com -- Have a topic idea or a guest you'd like to see in a future episode? Let us know in the comments or email editor@gunspodcast.us Never miss an episode! Subscribe to our YouTube channel or sign up for our newsletter to get the Guns Podcast delivered straight to your inbox each week. Buy our Merch! Visit Gunspodcast.us

Savannah Guthrie returned to New York City yesterday to The Today Show following the disappearance of her mother, Nancy Guthrie, who has been missing for five weeks. Mark analyzes what this situation could mean for Savannah and her family. In Minnesota, $19 billion went missing due to fraud - where did the money end up? Governor Tim Walz addressed the issue yesterday, but his answers raised more questions. Gayle King has signed a new deal with CBS News. Mark takes your calls! Mark interviews WOR weeknight host Jimmy Failla. Iran is seeking new leadership after the U.S. deposed the ayatollah. There is talk of his son, Mojtaba Khamenei, succeeding him. Democrats continue to oppose President Trump's actions, including the war in Iran, which Jimmy tries to make sense of.

Savannah Guthrie returned to New York City yesterday to The Today Show following the disappearance of her mother, Nancy Guthrie, who has been missing for five weeks. Mark analyzes what this situation could mean for Savannah and her family. In Minnesota, $19 billion went missing due to fraud - where did the money end up? Governor Tim Walz addressed the issue yesterday, but his answers raised more questions. Gayle King has signed a new deal with CBS News. Mark takes your calls! Mark interviews WOR weeknight host Jimmy Failla. Iran is seeking new leadership after the U.S. deposed the ayatollah. There is talk of his son, Mojtaba Khamenei, succeeding him. Democrats continue to oppose President Trump's actions, including the war in Iran, which Jimmy tries to make sense of.See omnystudio.com/listener for privacy information.

Dr. Marcin Kortylewski (Oligonucleotide therapies and applications Section Editor of Molecular Therapy Nucleic Acids) sits down with Dr. Norman Michael Drzeniek and Niklas Kotzian from the Berlin Institute of Health at Charité. Join them as they discuss their new article, mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells. Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Jessie, 80 ans, vit en Australie et n'a plus de contact avec sa fille ni ses petits-enfants depuis plusieurs années, après avoir été mise à l'écart de la famille. Elle exprime sa souffrance face à cette rupture et son besoin de comprendre les raisons de cet éloignement. Jessie cherche des conseils pour tenter de renouer le dialogue avec sa fille. Chaque soir, en direct, Caroline Dublanche accueille les auditeurs pour 2h30 d'échanges et de confidences. Pour participer, contactez l'émission au 09 69 39 10 11 (prix d'un appel local) ou sur parlonsnous@rtl.frHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this week's episode, Blood associate editor Dr. Laura Michaelis interviews Drs. Mark Sorial and Emmanuelle Passegue on their articles published in volume 147 issue 7 of Blood. Dr. Sorial discusses "Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium" where he and his team evaluated the prognostic significance of early relapse in a large retrospective cohort. They report a time to relapse of

Christin Godale, Executive Director of LifeSciKY, and Savannah Doliboa, Chief Commercial Officer at CTI and LifeSciKY board member, explore how purpose built infrastructure can unlock the next generation of medical breakthroughs in our latest podcast episode.Together, they discuss why infrastructure is often the missing link in drug development, how regional collaboration fuels innovation, and what success looks like when companies outgrow the incubator and scale locally. The conversation also shows the human side of ecosystem building by focusing on investing in people, nurturing talent, and turning scientific breakthroughs into real world impact.LifeSciKY is a mission driven hub designed to lower barriers for startups, accelerate early research, and strengthen Northern Kentucky's biotech ecosystem. Through affordable wet lab space, shared equipment, workforce development, STEM education, and community partnerships, it gives innovators the support they need to move discoveries from bench to patient.00:30 An overview of LifeSciKY as a mission driven life sciences hub supporting early stage innovation.01:45 Christin and Savannah share the vision behind LifeSciKY and how it benefits the region.04:00 How the lack of wet lab space stalled regional growth and why infrastructure is essential to moving medicine forward.06:45 Who LifeSciKY Is built for: startups, hybrid AI companies, and entrepreneurs looking to turn science into viable products.08:25 What success looks like for biotech, including formation, fundraising, and scaling beyond the incubator.10:15 How connecting academia, hospitals, industry, and government is building a regional life sciences ecosystem. 12:20 Affordable access, nonprofit mission, and hands on support sets LifeSciKY apart from other incubators.14:20 How multiple years of state support and leadership brought LifeSciKY to its grand opening.18:10 Workforce development and STEM outreach are building the next generation of life sciences talent.22:00 The future of LifeSciKY and why Northern Kentucky could become a biotech hub.23:10 Highlighting a LifeSciKY company developing more accessible CAR T therapies for children.25:00 Ways founders, students, and community members can engage with LifeSciKY.26:10 Reflections on momentum, mission, and future therapies.28:05 In their closing thoughts, Christian and Savannah explore excellence and growth.

Au sommaire : La guerre en Iran inquiète les marchés financiers, avec des baisses importantes à la Bourse de Paris et en Asie, notamment à cause de la fermeture du détroit d'Ormuz et de la hausse des prix du gaz et du pétrole.L'assurance chômage prévoit un déficit de 2,1 milliards d'euros cette année en raison de la dégradation du marché de l'emploi et des prélèvements exceptionnels du gouvernement.L'écart de rémunération entre les hommes et les femmes cadres s'est accentué, atteignant 16% en 2025 contre 12% en 2026, notamment à cause de la sous-représentation des femmes dans les postes les mieux rémunérés.Les cours de l'or et de l'argent sont en baisse, les investisseurs se tournant vers le dollar américain comme valeur refuge.La Commission européenne va présenter des propositions sur le "Made in Europe" pour se protéger de la concurrence chinoise.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

'Quebrar todos os dentes num assalto': mensagens de Daniel Vorcaro expõem ameaças contra opositores. Ator José Dumont é preso após ser condenado por estupro de vulnerável. Pesquisa aponta que 13,1% das vítimas de feminicídio tinham medida protetiva. Ataques se espalham pelo Oriente Médio: o 5º dia da guerra entre Irã, EUA e Israel. Cartão de crédito, empréstimo e cheque especial: veja as modalidades com maiores dívidas no país.

In this March mailbag episode of Art Ed Radio, Tim Bogatz is joined by Amanda Heyn to give some advice for the upcoming NAEA National Convention and answer a variety of other questions. From light topics like underrated artists to heavier discussions about career uncertainty, this episode again offers some real talk about the issues art teachers are facing right now. The episode wraps up with a look at the State of Art Ed survey, including discussions about curriculum, behavior management, and showcasing student artwork. Resources and Links Join the Art of Ed Community See all of the Community Events that Tim and Amanda mentioned! Check out the State of Art Ed results Making the Most of Your Conference Experience Getting Started Teaching Art on a Cart PRO Pack How to Work Smarter, Not Harder with Art on a Cart

Audio roundup of selected biopharma industry content from Scrip over the business week ended Feb.27, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Zealand CEO calls for end to weight loss Olympics; MSD on AI-assisted pipelines; Bruce Levine's CAR-T stories; biopharma dealmaking bounces back; and 2025 was a tough year for US IPOs. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-LTCVEH6JLFGRXBOQCFW6V72NVI/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Cancer is not a foreign invader. It is a failure of defense.  In this episode, Dr. Patrick Soon-Shiong, surgeon, scientist, inventor and one of the most influential figures in modern medicine, lays out a radical idea: your body already knows how to defeat cancer. The question is whether we are activating it… or suppressing it.  Born in apartheid South Africa and driven by what he calls a duty to fight for the underdog, Dr. Soon-Shiong went from performing complex surgeries in Los Angeles to inventing Abraxane, a breakthrough nanoparticle chemotherapy now used worldwide. But he believes chemotherapy was only chapter one, Chapter two is immunity.  He breaks down the role of the 450 million year old Natural Killer cell and why it may be the missing piece in cancer prevention, then dives into IL-15, once ranked the most promising molecule to cure cancer and now approved in 33 countries, with new ground in lung cancer treatment in Saudi Arabia.  Dr. Soon-Shiong also shares his warning of a coming "pandemic of cancer," the controversy around COVID vaccine development, the overlooked $10 blood test hidden inside routine labs that predicts mortality risk, and how camel nanobodies, AI and robotics may democratize treatments that once cost $1 million.  If you care about longevity, cancer prevention, or the future of medicine, this episode matters.    Timestamps:  00:00 – First impressions of the Middle East and the crisis of trust  08:17 – What cancer really is and the role of the Natural Killer cell  14:08 – The warning: a possible pandemic of cancer in young people  16:47 – The T-cell COVID vaccine controversy  24:40 – IL-15: ranked the #1 molecule to cure cancer  29:07 – Breaking news: approvals in 33 countries and Saudi Arabia  31:06 – Immunity, aging, and the link to longevity  37:53 – The $10 blood test hidden in plain sight for 30 years  39:28 – Why camels and sharks don't get cancer  44:32 – From apartheid South Africa to billionaire inventor  48:13 – Turning $1 million CAR-T therapy into a $25,000 robotic solution  50:33 – Why the Middle East could lead the next biotech revolution    Follow Spencer Lodge on Social Media:  https://www.instagram.com/madeindubaipodcast/?hl=en  https://www.instagram.com/spencer.lodge/?hl=en  https://www.tiktok.com/@spencer.lodge  https://www.linkedin.com/in/spencerlodge/  https://www.youtube.com/c/SpencerLodgeTV  https://www.facebook.com/spencerlodgeofficial/  https://www.facebook.com/profile.php?id=61586194260076    Follow Dr. Patrick Soon-Shiong on Social Media:  https://x.com/DrPatrick

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and regulatory evolutions shaping the landscape of medicine.One of the most significant recent developments involves Boehringer Ingelheim's drug Hernexeos, which has seen a rapid expansion in its use as a first-line treatment for non-small cell lung cancer (NSCLC). This expansion was made possible through the FDA's Commissioner's National Priority Voucher, an initiative designed to fast-track the approval of treatments addressing critical needs. This rapid progression highlights a commitment to accelerating access to crucial oncological treatments, emphasizing the role of accelerated regulatory pathways in swiftly delivering innovative therapies to patients who need them the most.In oncology, a combination therapy involving Padcev and Keytruda is showing promising results in improving overall survival rates for patients with muscle-invasive bladder cancer who are eligible for cisplatin. However, the continuously evolving landscape of treatment options for this cancer type means that further evaluation is necessary. This scenario highlights the ever-changing nature of oncology strategies and the ongoing need for clinical validation to determine the most effective treatment regimens.Switching gears to immunology, UCB's Bimzelx has reached a significant sales milestone, reflecting its growing influence in treating multiple indications. This success points to an expanding market for immunology therapeutics, as the industry remains focused on developing blockbuster treatments that can serve various conditions effectively.On the regulatory front, Moderna's combination influenza/COVID-19 vaccine has received a positive review from the European Medicines Agency's Committee for Medicinal Products for Human Use. This green light exemplifies the EU's dedication to thorough scientific evaluations. It contrasts with the FDA, which has exhibited hesitancy in this area, highlighting how varying regulatory approaches can affect drug availability in different regions.The field of HIV treatment is also seeing progress with GSK's ViiV division confirming the efficacy of its long-acting Cabenuva regimen for adolescents over a 96-week period. This long-acting regimen provides an alternative to daily oral therapies, potentially improving adherence and outcomes among younger populations—a crucial factor in managing chronic conditions effectively.Meanwhile, legal developments are stirring as the debate over "skinny labeling" for generic drugs reaches a pivotal point. The U.S. Supreme Court is being urged to overturn a ruling that endangers this pathway, highlighting the fine balance between fostering generic drug competition and protecting pharmaceutical innovation. In related legislative discussions, a Senate hearing focused on the FDA's rare disease review process has brought to light concerns about bureaucratic obstacles that may slow innovation. There is a call from stakeholders for more streamlined processes to ensure timely access to treatments for rare diseases—a sentiment echoed by many in the industry.The burgeoning field of CAR-T cell therapies continues to make waves, especially against solid tumors. Recent preclinical studies have shown potential efficacy in eradicating solid tumors in mice models. Despite these promising findings, significant regulatory challenges remain, and streamlining approval processes could accelerate their clinical application.In other significant news within the industry, Novartis has completed its acquisition of Avidity Biosciences for $12 billion, leading to the creation of Atrium Therapeutics. With a capitalization of $270 million, Atrium emerges with two promising preclinical candidates targeting cardiovascular conditions, signaling potential advSupport the show

For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases. But the application of these engineered cell therapies is expanding to reset the immune system for patients living with lupus, stiff person syndrome and other autoimmune conditions. And with new frontiers come new rules. In this week’s episode of "The Top Line," Fierce Pharma’s Angus Liu chats with Harpreet Singh, M.D., chief medical officer at Precision for Medicine and a former director of the FDA's Division of Oncology, about a recent article by FDA officials led by CBER Director Vinay Prasad, M.D., laying out the agency’s perspective on its regulation of autoimmune CAR-T therapies. Singh discusses how the agency’s "case-by-case" approach, as indicated in the article, could be similar to—and different from—CAR-T for oncology indications. She also talks about how drug developers should follow existing development experience, as well as prepare for specific requirements for long-term patient follow-up and potential new clinical endpoints from the agency. To learn more about the topics in this episode: FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial See omnystudio.com/listener for privacy information.

La ciencia española lidera mundialmente los trasplantes. Amelia Escolano, desde Filadelfia, investiga una innovadora vacuna contra el VIH que induce anticuerpos neutralizantes y muestra potencial para otros virus mutantes. España también deposita semillas de olivo en Svalbard para preservar la diversidad genética agrícola. Las enfermedades raras encuentran esperanza en la terapia génica. La Fundación Columbus impulsa esta técnica que corrige información genética defectuosa con éxitos en patologías monogénicas, aunque el coste y la falta de ánimo de lucro para casos ultrarraros son desafíos. Las terapias CAR-T, llamados "medicamentos vivientes", prometen contra el cáncer al modificar células T del paciente para atacar tumores. Tenerife registra un enjambre sísmico en el Teide, bajo vigilancia y sin indicios de erupción inminente. En economía, la inflación española se mantiene en el 2.3% en febrero (subyacente 2.7%), superando la media europea, afectando la competitividad con alimentos ...

Au sommaire : Netflix refuse de relever son offre pour le rachat du groupe Warner Bros Discovery, ouvrant la voie à Paramount Skydance qui propose une valorisation de 110 milliards de dollars pour le groupe.L'Ukraine ouvre une usine de production de drones au Royaume-Uni, un investissement de 230 millions d'euros pour sécuriser la production et répondre aux besoins de ses troupes.Stellantis enregistre une perte record de 22,3 milliards d'euros en 2025, liée à des charges de repositionnement stratégique du groupe.Malgré une baisse des ventes de 2%, l'équipementier automobile Valeo affiche un bénéfice de 200 000 euros et prévoit une hausse de 23% de son bénéfice en 2025.La SNCF dégage un bénéfice de 1,8 milliard d'euros en 2025 grâce à un retour du trafic passager à des niveaux d'avant-Covid.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Procurez-vous le livre de Fabien OlicardToutes les infos sur son site fabienolicard.fr--COACHING RELATION À L'ARGENT

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CAR T‑cell therapy is redefining what personalized cancer treatment can look like, offering real promise for patients and families. In this episode, we speak with Dr. Richard Maziarz and CAR T Nurse Coordinator Bashi Ratterree of Oregon Health & Science University (OHSU). Together, they explain how CAR T‑cell therapy works, who may be eligible, what patients can expect during treatment and recovery, and the promising advancements shaping the future of this innovative therapy. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: CAR T-cell therapy Clinical Trial Support Center CAR T-Cell Therapy: A Path of Hope and Healing Video Series Bloodline Breakthroughs: innovations and inspiration video podcast: CAR T-cell Therapy Hematology Horizons vlog: CAR T-Cell Therapy and the Patient Experience CAR T-Cell Therapy: Side Effects video Additional Blood Cancer United Support Resources: Information Specialists Financial support Online Chat Free Nutrition Consultations Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; Kite, a Gilead Company; Novartis Pharmaceuticals Corporation. The post Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives first appeared on The Bloodline with Blood Cancer United Podcast.

Bhavana (Tina) Bhatnagar, DO—Associate Professor of Medicine at the WVU Cancer Institute—shares her journey from academic centers to rural West Virginia, where she's working to expand access and improve outcomes for underserved communities. We talk about what high-quality rural cancer care really takes: overcoming transportation and financial barriers, navigating limited specialty resources, building community-based clinical trials, and expanding access to innovations like CAR T—powered by strong multidisciplinary teams.Key takeaway: the best care starts with understanding the person behind the patient.

This review series focuses on recent advances in resolving macro and molecular structures that have driven the field of occlusive thrombus structure and function forward. Covering multiple contributions to thrombosis, eg, platelets, factor XIII, and the contact system, the series also looks to put this new knowledge into the context of future advances in diagnostic and therapeutic tools to enhance normal hemostasis while preventing and treating unwanted thrombosis. Blood Associate Editor, Dr. Thomas Ortel discusses this series with Drs. Alisa Wolberg, Jonas Emsley, and John Weisel, who all contributed to articles in the Review Series on the Structural Underpinnings of Hemostatic Plugs and Thrombotic Occulsions which can be found in volume 146, issue 12 of Blood. 

Drew is the inventor of Caroline's Cart, a game-changing, patented, special-needs shopping cart designed to provide an inclusive and accessible shopping experience for individuals with special needs. Inspired by her daughter Caroline, who has special needs and could not use a traditional cart, Drew Ann took matters into her own hands—sketching her first idea on a napkin and eventually bringing the patented design to life. Today, Caroline's Cart is in retailers across all 50 states and eight countries, used by families, caregivers, senior adults, and stores committed to inclusion, accessibility and dignity.   www.autismresourceproject.org/podcast

Convidada: Marina Pera, analista sênior de risco político da consultoria Control Risks no México. O chefão do cartel Jalisco Nova Geração, um dos mais violentos e poderosos grupos criminosos organizados do México, foi morto no último domingo (22). O megatraficante Nemesio Oseguera Cervantes, conhecido como "El Mencho", foi baleado em uma operação das forças de segurança mexicanas: os agentes monitoraram os passos de sua namorada até uma cabana em Tapalpa, na região montanhosa do estado de Jalisco, onde se deu o confronto. A morte de El Mencho foi o gatilho para uma reação violenta do grupo organizado. Ataques foram registrados em 20 estados mexicanos: criminosos incendiaram veículos, bloquearam rodovias, fecharam escolas e espalharam pânico. O número de mortos já passa de 70, entre policiais, agentes penitenciários e integrantes do cartel. O governo mobilizou mais de 10 mil militares para conter a violência. A morte do chefe do Jalisco Nova Geração abre uma nova fase de incertezas no México, afirma Marina Pera, analista sênior de risco político da consultoria Control Risks no México. Em entrevista a Natuza Nery, ela descreve como El Mencho mantinha seu poder e cultivava uma imagem messiânica diante de seu grupo. Marina também explica por que a queda de uma liderança desse tamanho pode desencadear uma avalanche na estrutura do narcotráfico e nas instituições oficiais mexicanas.

Guest: Dr. Ido Amit is a Principal Investigator and the Eden and Steven Romick Professorial Chair at the Weizmann Institute of Science. His lab is at the forefront of developing and applying cutting-edge single-cell genomics technologies alongside advanced computational approaches. By integrating these innovative tools in both animal models and human studies, his team uncovers the immune regulatory mechanisms and pathways that shape health and disease. Featured Products and Resources: Stay up-to-date with the latest in human immunology news. Download a free wallchart on the production of CAR T cells. The Immunology Science Round Up Modified RNA Prevents Autoimmunity – Researchers show that modified RNA from our own cells naturally blocks TLR7 and TLR8, preventing harmful immune activation. Oncolytic Virus Boosts T Cells – In glioblastoma patients, a single virus treatment helped the immune system attack the tumor. Rewiring the Immune System During Food Scarcity – When food is scarce, stress hormones rebalance the immune system to fight infection while conserving glucose and preserving immune memory. Regulating Bystander T Cells – IL-4 can dial down how strongly memory CD8+ T cells respond to infection without direct antigen stimulation. Image courtesy of Dr. Ido Amit Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

BUFFALO, NY – February 25, 2026 – A new #editorial perspective was #published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.” Led by Uzma Saqib — with corresponding author Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya — the perspective reviews recent clinical and translational advances in chimeric antigen receptor T-cell (CAR-T) therapy and highlights both its promise and its remaining barriers. The piece synthesizes recent clinical advances in hematologic malignancies and emerging applications in solid tumors, while focusing attention on safety (for example, cytokine release syndrome and neurotoxicity), resistance, antigen specificity, and access disparities. The authors summarize the CAR-T workflow (leukapheresis → genetic modification and expansion → infusion) and note major recent clinical gains — including improved outcomes in leukemia, lymphoma, and multiple myeloma — that support wider adoption of cellular immunotherapy approaches. They emphasize that despite these advances, important clinical challenges remain, particularly for solid tumors, where antigen selection, tumor microenvironment, and T-cell trafficking limit efficacy. At the same time, the perspective highlights technological and clinical strategies under development to overcome these obstacles, including next-generation CAR designs and improved supportive-care protocols. “Despite its promise, CAR T-cell therapy faces several critical challenges.” The authors call out clear next steps for the field: (1) continued refinement of CAR constructs (dual-targeting, switchable/on-off systems, armored CARs) to improve specificity and reduce on-target/off-tumor toxicity; (2) improved management protocols and prophylactic measures to mitigate CRS and neurotoxicity; (3) expanded investigation of allogeneic or alternative CAR-T platforms to address manufacturing, cost, and access barriers; and (4) focused translational studies to improve T-cell trafficking and efficacy in solid tumors. They also highlight equity issues — socioeconomic and racial disparities that limit access to CAR-T — and urge that broad deployment plans include strategies to expand availability and affordability. DOI - https://doi.org/10.18632/oncotarget.28836 Correspondence to - Krishnan Hajela - hajelak@gmail.com Abstract video - https://www.youtube.com/watch?v=T4hbwPToVKI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28836 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, CAR-T therapy, therapeutic approaches To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disease Week, providing draft guidance on its new plausible mechanism pathway, while a bipartisan senate hearing on Thursday will focus on the authorization process for rare conditions; Another leadership change shakes up CDC; and Gilead acquires CAR T partner Arcellx for nearly $8 billion.  Everything is coming up Lilly. The Indianapolis-based pharma bested its chief rival, Novo Nordisk in a head-to-head test. In a Phase 3 trial initiated by Novo itself, Lilly's Zepbound generated 25.5% weight loss while the Danish pharma's CagriSema elicited 23%. The results sent Novo's shares plummeting by an unprecedented 20% to a pre-Wegovy valuation while Lilly's market cap continues to climb.   Novo attempted a comeback on Tuesday, announcing that its triple-G agonist UBT251 scored almost 20% weight loss after 24 weeks in a Phase 2 trial in China. By comparison, Lilly's own triple-G competitor retatrutide led to 17.5% weight loss over the same timeframe, according to BMO Capital Markets analysts. Novo also sweetened the pot, announcing that it would slash the prices for all three of its GLP-1 medicines starting in 2027.    Meanwhile, the FDA kicked off Rare Disease Week with draft guidance on the new Plausible Mechanism Pathway for personalized therapies that was first teased in November. Jumping off last summer's Baby KJ success story, the new pathway is aimed at advancing treatments for ultra-rare diseases. And a bipartisan senate hearing on Thursday will focus on the authorization process for rare disease therapies.  While the rare disease space has enjoyed recent regulatory progress, funding these vital therapies remains a challenge. Companies like the Orphan Therapeutics Accelerator (OTXL), a non-profit biotech, are trying to change this with creative approaches including tax exempt status and unique partnerships with CDMOs and CMOs. Finally, in a move that also has implication for the rare disease space, the FDA's official pivot from a two clinical trial requirement to just one for new drug applications is lighting up biopharma social media.   And over at the CDC, there is more upheaval on the leadership front as National Institutes of Health Director Jay Bhattacharya replaces acting director Jim O'Neill as head of the agency, and principal deputy director Ralph Abraham steps down, citing “unforeseen family obligations.”    On the business front, Gilead inked the biggest M&A deal of the year so far, acquiring CAR T partner Arcellx for nearly $8B. And Merck's Keytruda should have a few extra years of dominance thanks to a web of patents, with billions on the line. Check it out in BioPharm Executive, in your inboxes Wednesday.  HostsJef Akst, Managing Editor, BioSpaceHeather McKenzie, Senior Editor, BioSpaceAnnalee Armstrong, Senior Editor, BioSpace

Immune discusses how tattoo ink accumulates in lymph nodes, promotes inflammation and influences response to two different vaccines. Hosts: Vincent Racaniello, Cindy Leifer, Stephanie Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server IL-9, CAR T cells and anti-tumor CD8 cells Tattoo ink, inflammation and vaccines Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

This month, the gals welcome back their pal Robbie Knutsen to scream about mermaids in public, niche children's birthday party themes, Pentagon plugs, twisted panties, crocodile tears, and modern grave robbing. Tune in for February's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.   0:00 Introduction 11:26 Headlines 45:24 Coven Confessions 1:16:15 Coroner Corner

…ON TODAYS PROGRAM…   FERNANDO AND THE HONDA CURSE, LAWRENCE STROLL SELLS ASTON MARTIN NAMING RIGHTS FOR 50 MILLION POUNDS. FERRARI ON THE OTHER HAND SHOW OFF NEW SPINNING REAR WING AND, LOOK VERY COMPETITIVE ! MCLAREN AND MERCEDES ARE NOT FAR BEHIND… RED BULL IS STILL A QUESTION MARK?…AND FERNANDO WILL NEED HIS CAMPING CHAIR AS THE GP2 ENGINE THAT FAILED HIM AT MCLAREN, THAT WENT KABLAMO IN THE INDY 500 AND LOOKS TO HAUNT ALONSO FOR ANOTHER LONG SEASON!! STAY TUNED FOR SOME GREAT ONE LINERS FROM MACHISMO… THIS WEEK'S NASIR HAMEED CORNER…MORE VINTAGE BANTER BETWEEN THE HOST AND NASIR…THIS WEEKS SPECIAL GUEST: MARCUS ERICSSON, MARTIN BRUNDLE, AND MIKI MONRAS DE ESPANA…! Indianapolis 500 Veteran Hucul Dies at 79   INDIANAPOLIS (Friday, Feb. 20, 2026) – Canadian driver Cliff Hucul, a veteran of three Indianapolis 500 starts in the late 1970s, died Feb. 17 on his farm in his native Prince George, British Columbia. He was 79. Hucul made three consecutive starts in “The Greatest Spectacle in Racing” from 1977-79. His best finish came as a rookie in 1977, 22nd in the No. 29 Team Canada McLaren/Offenhauser that Hucul bought after Johnny Rutherford drove it to victory in the 1976 “500.” Hucul completed 72 laps before being sidelined by gearbox problems. He qualified on Bump Day for that race despite touching the wall in practice the previous day and suffering two engine failures during the Month of May, a significant pitfall for his low-budget team. Hucul's best qualifying spot was 18th in 1979, his final “500” start. The small-town driver from northern British Columbia learned his craft by racing stock cars and modified sprint cars at local tracks. He then began racing modifieds and supermodifieds in the Pacific Northwest against drivers that included eventual Indianapolis 500 winner and INDYCAR SERIES champion Tom Sneva and his brother Jerry Sneva. Hucul made 24 total USAC and CART starts between 1977-81, with eight top-10 finishes. Hucul's best finish in the standings was 11th in 1979, when he started the season by placing fifth at Ontario Motor Speedway and a career-best fourth at Texas World Speedway. In 1996, Hucul became a paraplegic after an automobile accident when crossing black ice on a highway in British Columbia. Despite being confined to a wheelchair, Hucul remained active, managing his farm and mentoring many drivers in the area. He was inducted into the Prince George Sports Hall of Fame for his lifetime contributions to auto racing. Hucul is survived by his son, Kelly, and daughter-in-law, Sylvie; daughter, Michele, and many grandchildren. 2026 BAHRAIN TESTING - WEEK 1, DAY 3 MAX VERSTAPPEN “Looking at the test overall, the Team got in a good number of laps on the first day so we were happy with that. We completed a lot of things that we wanted to test with the new Power Unit and the car in general. Today it was a continuation of that plus also trying to explore a little bit more with the car; you go through so many test items that it continues to change and evolve with everything that you are testing. In general, it is all so new that we are still learning a lot, but the car was good. We also have new tyres, so we spent some time looking at different sets and understanding what we need to improve and be better at. With the power unit, looking at the laps we got on the board, the start that we have had is good. That's exactly what we wanted to do and it was not a given. Whether it will be enough to win races, we don't know, we will just focus on ourselves and try to do the best we can, but there is still massive room for improvement. Finally, with the car, we learnt a lot about what worked and what didn't. Our runs also gave us even more ideas for the afternoon with Isack and then for next week, where we can continue to try new things and different set ups.” ISACK HADJAR “The first week here in Bahrain has gone well. Of course, I had to wait a little before getting in the car after Barcelona, but once I did, we were able to put it to the test and really work through what we need ahead of next week and Melbourne. There are so many things to look at, but we're staying on track with our programme so far. True performance and pace are always hard to judge in pre-season, but we can be happy with the reliability we've had from the power unit this week. There are still things to work on in terms of balance and tyre management, but that's completely normal for this time of year. We're working through it together as a Team to get where we want to be for Australia. I've known the people here for a while now, but it's great to be working with them again in an environment like this." ASTON MARTIN The Aston Martin Aramco Formula One™ Team concluded its testing programme at the Bahrain International Circuit today, with Lance Stroll returning to the cockpit of the AMR26 for the final time before the Australian Grand Prix. Lance did not get on track until late in the morning session due to a battery-related issue that had impacted Fernando's running yesterday. Honda carried out simulations on the test bench at HRC Sakura before the car returned to the track. Due to a shortage of power unit parts, the run plan was very limited and consisted only of short stints. Lance Stroll “It's been a challenging couple of weeks here in Bahrain, and today's limited running wasn't the way we wanted to finish the second test. It's clear the car isn't where we want it to be performance-wise, and we know there's a lot of work ahead in the coming weeks and months. There's a long season ahead, and we'll keep pushing flat out to unlock more performance. I want to say a big thank you to everyone trackside and back at the AMRTC for the work that's gone in so far. It's not where we want to be right now, but I know how determined this team is. We'll stick together, rise to the challenge and keep working until we deliver the performance we are looking for.” WILLIAMS F1 2026 Bahrain pre-season testing – Day 3 James Vowles, Team Principal: Another solid day of running and mileage. It's great to see that across the last six days of testing, we've been predominantly tyre and time limited, and able to complete the full programme that we wanted. That's just a testament to the hard work of the teams, both here and in Grove, making sure that we made up for lost time. 
 No one truly knows where all the performance lies. That's what Melbourne is all about, so I can't wait to go there, to gain a further understanding of where we are. What I know for sure, though, is we have work to do. There's no doubt about it. We've put ourselves on the back foot. But my assurance to everyone is that we have an aggressive programme lining up in front of us in order to make sure that we extract as much performance in this car as possible over the forthcoming months. Carlos Sainz: The past six days of testing in Bahrain has been one of the most interesting and challenging tests that I've been part of, given the new regulations and number of things we had to learn. The progress from day one has been significant, although there are still going to be things to understand and solve at the start of the season. We go into the first half of the year with lower expectations than 2025 knowing that we'll be starting slightly on the back foot. However, I'm really looking forward to getting started and focusing on improving the cars through the year to become more competitive. Bring on Melbourne! Alex Albon: It's been a relatively smooth test here in Bahrain. We got some good mileage under our belts and tested everything we wanted to get out of the car, so I'm feeling more ready for Melbourne. There's still a lot we need to understand and plenty of performance left on the table that we need to extract, but I'm glad the tests went to plan. It's now all about maximising the next few days to prepare for the first race of the year! THIS WEEK'S INTERVIEW WITH MIKI MONRAS... Miki Monrás on battling Bottas and Ricciardo in the late 2000s and the rising cost of junior racing In the late 2000s, Miki Monrás was one of Spain's brightest prospects on the junior single-seater ladder, trading blows with the likes of Daniel Ricciardo, Valtteri Bottas and António Félix da Costa in Formula Renault and GP3. But while his rivals pushed on towards F1 or careers in GTs, the Spaniard's single-seater journey came to an abrupt halt in 2011. Feeder Series caught up with Monrás to reflect on the times he rubbed shoulders with greatness, the challenges of racing in the post–financial crisis era, and life beyond motorsport. By Anabelle Bremner Back in the noughties, the path from karting to Formula 1 looked nothing like it does today. There was no standardised Formula 4, no carefully managed ladder – just a patchwork of championships that rewarded those brave enough, and wealthy enough, to dive straight in. Eurocup Formula Renault 2.0 was as deep as it got: 40-car grids stacked with future stars, the proving ground where Pierre Gasly, Nyck de Vries and Lando Norris would come to cut their teeth. But before all of them, it was Monrás in the thick of it. He made his single-seater debut in late 2007, the result of years spent chasing speed. His first taste of racing, in fact, came on two wheels – on a motocross bike, inspired by his father, who had raced professionally in Spain and Europe. At the age of eight, Monrás joined a motocross camp, and it wasn't long before karting came calling. “After the first race, I really enjoyed it,” he recalls. “I remember it was Christmastime and I asked for a motocross scooter and for a go-kart. So I finally got the go-kart, and that's the way I started. Then I started racing in Catalonia, and I just moved through Spain and Europe and all the world championships until formula.” Single-seater racing, however, would prove a unique beast. Shortly before turning 16, Monrás moved straight from karting into Formula Renault 2.0, in which the competition was fierce. “Normally at that age you'd go before to a category not straight to 2.0,” he said. “My first year I was racing with Bottas, I was racing with Ricciardo, I was racing with [Andrea] Caldarelli – really good drivers.… I was racing against people that were already racing for two years in single-seaters. That was a big difference.”His first Eurocup campaign, in 2008, proved a challenging one. He was scoreless for his first five rounds with the Hitech Junior Team (no relation to the current Hitech) before a switch to SG Formula brought him six points in the final two rounds. Valtteri Bottas, then of Motopark Academy, went on to claim that year's title after a close fight involving Ricciardo, Caldarelli and Roberto Merhi. The next year brought Monrás a decidedly better season and three podiums with SG Formula, owned by Mercedes Junior Team advisor Stéphane Guerin. He wound up fifth overall in a season dominated by a fierce three-way fight between Félix da Costa, Jean-Éric Vergne and Albert Costa – the last of whom ultimately took the title. Racing against so much talent at such a young age left Monrás with plenty of perspective on what might have been. “Ricciardo was my teammate. Jean-Éric Vergne was my teammate. I raced with Da Costa, Bottas, with Magnussen, so many people that have been racing each other and winning races,” he said. “[I] think if I changed something at that point, maybe I would be in Formula 1, but who knows. Maybe yes, maybe no. “But at that time, it was really difficult times because it was 2010, '11, '12, where there was also a big crisis in the world, especially in Europe. It was really difficult for Spanish drivers to get the sponsors and the money to race.” The financial squeeze triggered by the 2008 global financial crisis left Monrás and many of his peers in a precarious position. Several teams, such as SG Formula, shut their doors in the wake of the crisis amidst an already shifting landscape in junior racing. “It's been changing a lot from that time until now. When I was racing Eurocup 2.0, one time we were like 48 drivers, I remember. 2008 at Spa. It was a massive level and so many drivers wanted to go in,” he said. “Eurocup was really high level, I would say maybe [comparable] to Formula 4 about the car and the lap times. “Motorsport has changed a lot in the last few years. It's more expensive. At that time, Eurocup was also expensive, but I think Formula 4 is around €700,000 more or less, maybe more now. It's quite expensive. Back then, I think Eurocup was around €300,000 or €250,000, so there was a massive difference. A lot more people could race at that time.” After two and a half years competing in various Formula Renault series, Monrás stepped up to GP3 in 2010. The inaugural season, won by eventual F1 driver Esteban Gutiérrez, came with another steep learning curve. Monrás managed two podiums and a 10th-place finish in the standings, but the step up exposed the limits of what talent alone could achieve in a field packed with hungry, well-backed drivers. “When I raced GP3, that was the first year of the championship, so it was a new championship for all of the teams. I also raced with Arden, which was a new team in the category, so it made it a bit difficult,” he said. “During testing, I remember I was flying in GP3, and then suddenly in some races there was such a huge difference with some other cars and drivers. It was difficult sometimes. … I think this is always present in motorsport in all categories. You will find some kind of differences within cars and teams. It just will always be there.” Challenging as it was, that season had its highs for Monrás. A recovery drive in Spa's characteristic rain remains a fond memory for the Spaniard. “I had a really bad qualifying because there were some yellow flags,” he explained. “Because there were 30 cars, it was easy to find yellow flags if you're waiting for the last minutes in qualifying. I finished [ninth in] race one, and in race two it started raining really heavily after five laps. I went from P10 to P3, nearly fighting for the win in the last lap against Rossi and Tambay. That was a really good race.” After a season in GP3, Monrás moved up a rung on the ladder to Formula Two. At the time, the feeder series landscape was fragmented. GP2 and Formula Renault 3.5 offered established paths to Formula 1, while the MotorSport Vision's FIA Formula Two Championship, which first ran in 2009, aimed to do the same with a more affordable package. “Formula Two at that point was very competitive, economically speaking,” Monrás said. “It was a lot cheaper to race in Formula Two than race in GP2 at that moment or 3.5 because it was like all one team. All the cars were one team with different engineers, and that made it low cost for the time. “A lot of drivers went to it because of that. They were racing in the best tracks, same as World Series and similar to GP2, and the car was competitive. Maybe not as competitive as GP2 or 3.5 because it was a bit slower, but it was really competitive and really fast, on the straight especially.”  “In that time, what they were saying was it was very equal. You had one engineer for three cars, you were sharing data with these three cars, and it was all under the same team. You can always find differences in motorsport. Maybe not a difference to make one car win and one car P15, but you can still always find two-tenths difference in similar cars, and two tenths, sometimes it's a lot of time,” he said. “The cars were on the same team, but each engineer was doing the set-up for his driver. The set-up I was using and maybe the set-up Bortolotti was using, he had won the championship maybe from our different set-ups. Every race, you changed engineers. Every weekend, you were rotating engineers so at the end of the season, everybody worked with everyone.” By 2012, the funding had dried up. Monrás was left sponsorless and unable to compete in Formula Two. He sampled GT racing in the Blancpain Endurance Series and tested with both Audi Sport and Atech GP, but no program materialised. From there, Monrás transitioned into driver coaching and team management – mostly with the AV Formula team owned by his manager, Adrian Vallés – and eventually “moved on” from motorsport around 2017. “I was working also with McLaren Automotive, but it was not motorsport. It was automotive, developing road cars, really competitive cars. After that I decided to stop because I wanted to follow a new career professionally, and I moved onto real estate which I have always been [involved with] because of my family, so that's why I decided to move over,” he said. “I now work in a real estate company which I own with some partners, and that's my day-to-day nowadays.” After years climbing the ladder in lockstep with some of the sport's future stars, Monrás has found a new rhythm – one that's decidedly less fast, but no less his own. Yet his career remains a reminder of the talent that defined an era: a Spaniard who went wheel to wheel with the likes of Ricciardo, Bottas, and Vergne, racing in some of the deepest junior grids of the 2000s and 2010s. In the story of that generation, Monrás may no longer be on track, but he's never far from the memory of it all.

Narrativas analisa os acontecimentos do Brasil e do mundo sob diferentes perspectivas.     Com apresentação de #MadeleineLacsko, o programa desmonta discursos, expõe fake news e discute os impactos das narrativas na sociedade.     Abordando temas como geopolítica, comunicação e mídia, traz uma visão aprofundada   e esclarecedora sobre o mundo atual.     Ao vivo de segunda a sexta-feira às 17h.   Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay:   https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br #Janja #Lula #CartaoCorporativo #PoliticaBrasileira #GastosPublicos #NoticiasBrasil #GovernoLula #Transparencia #Economia #BrasilHoje #PortalDaTransparencia #JanjaLula #DinheiroPublico

Alexandre Garcia comenta sobre gastos do governo Lula, a necessidade de transparência no caso Master e maioridade penal. 

Ever notice how your Etsy shop gets a lot of "Add to Cart" activity… but not a lot of purchases? You're not alone. In this episode, we break down why shoppers use "Add to Cart" so often in ecommerce , and why it doesn't mean they're ready to buy. Here is that creepy video I talked about - brace yourself. - https://www.youtube.com/watch?v=Ntf5_ue2Lzw&t=294s Join my skool group if your not too creeped out - https://www.skool.com/grow-my-etsy-shop-3051  

Álvaro Gribel, repórter especial e colunista do Estadão, comenta os principais assuntos da Economia e Política nacionais no Jornal Eldorado, às 2ªs, 4ªs e 6ªs, às 8h30.See omnystudio.com/listener for privacy information.

@katiucha e @OdeioPePe querem saber: você assumiria uma traição em rede internacional para ter seu paquera de volta? Se o crime não compensa, como uma cartãozeira ganhou medalha de ouro? Esse e outros questionamentos no episódio 113 do VortexOferta especial nos planos usando o nosso link no Nordvpn: https://nordvpn.com/vortexpodou CUPOM: VORTEXPODAcesse o link do Vortex e ganhe DESCONTO ESPECIAL  na sua matrícula na Alura: https://www.alura.com.br/vortexou CUPOM: VORTEX Host: Katiucha Barcelos. Instagram: @katbarcelos | Twitter/X: @katiuchaCo-Host: Pedro Pinheiro. Instagram: @odeiopepe | Twitter/X: @OdeioPePeInstagram: @feedvortexBluesky: @feedvortex.bsky.sociaTwitter: @feedvortexTiktok: @feedvortexReddit: r/feedvortexGrupo paralelo não-oficial do Vortex no telegram: https://t.me/+BHlkG92BfPU5ZjdhEsse grupo é dos ouvintes, para os ouvintes e pelos ouvintes. Não temos qualquer afiliação oficial ou responsabilidade por QUALQUER COISA falada neste grupoLink do post do episódio nas redes sociais:InstagramTwitterLinks comentados no episódio:Pronuncia do Sobrenome do LucasLucas Pinheiro cantando o hino do Brasil  Localização perfeita para uma olimpíada de inverno Acusação de trapaça vira polêmica no curling com xingamento e pedido de VARCurling: Canadá vive nova polêmica nos Jogos de Inverno de 2026 após acusação de trapaça no time masculinoVídeo da atleta canadense também SUPOSTAMENTE usando o dedinhoShaidorov se vestiu como Po , da franquia Kung Fu Panda, durante o evento de gala do Campeonato Mundial de 2025Rotina de Duna do medalhista de ouroAmericano dá mortal na patinação artistica, movimento que foi banido por anosNorueguês ganha medalha e confessa traiçãoResposta da NamoradaFugitivo eslovaco capturado quando tentou assistir hóquei olímpicoBatedora de carteira fa França leva ouroEstoque de camisinhas acaba na Vila Olímpica dos Jogos de Inverno, e 10 mil preservativos são repostos: 'Terminaram em 3 dias'Ex-atleta olímpica alemã revela por que há tantas relações sexuais entre atletas durante os Jogos OlímpicosProdução: Thyara Castro, Bruno Azevedo e Aparecido SantosEdição: Joel SukeIlustração da capa: Brann Sousa 

AITA: For not giving someone my cart at Aldi's, DIRT ALERT: Gene Hackman estate update, an appreciation moment for "The Birdcage," and Jason's upcoming junket trip to Beverly HillsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Pre-Launch Strategy That Changes Everything What if your audience was already excited to buy before you ever opened the cart? That's the dream, right? No scrambling in the final hours. No sending more emails than you planned. No pushing harder than feels good and still wondering why it's not converting. I'm sitting down with Brenna McGowan, launch strategist and creator of Anticipation Marketing, to talk about the phase of launching most people skip over entirely. And honestly, it's the phase that makes or breaks your results. Here's what I've learned from my own launches and from watching thousands of my students do theirs: most people think they're doing the pre-launch part right. They mention what's coming in the P.S. of an email. They post about it on social and put up a waitlist. They feel like they're doing everything they're supposed to be doing. But then the cart opens and it still feels harder than it should. They're white-knuckling their way through launch week, and by the end of it, they're exhausted and wondering what went wrong. Is it the offer? Is it the audience? Is it just harder to sell right now? Usually, it's none of those things. It's the pre-launch. And that's what we're fixing today. RESOURCES MENTIONED IN THIS EPISODE: You've built something real. Revenue, audience, offers that work. But the results still don't match what you know you're capable of. The Revenue Consistency Formula is a FREE Live training for six-figure female founders who are done with inconsistent results and ready to understand what's out of sync so their messaging, offers, and lead generation can finally work together. Click here to register now. Learn More About Brenna McGowan Find Brenna McGowan on Instagram The Pre-Launch Plan Program HERE ARE THE 3 KEY TAKEAWAYS FROM THIS EPISODE: 1️⃣ A Waitlist Is Not a Pre-Launch — Posting "join the waitlist" isn't warming your audience up in the way you think it is. A real pre-launch builds belief in the problem, belief in the solution, and belief that you are the person to help them get there. When that's in place, you don't have to convince anyone when the cart opens. They're already in. 2️⃣ Sell the Process, Not the Program — During pre-launch, you shouldn't be talking about your course or your offer. Your job is to get your audience to believe in the method behind it. Brenna calls this belief-shifting, and it's the difference between an audience that's ready to buy and one that stays on the fence. 3️⃣ Anticipation Beats Urgency — Emphasizing the countdown used to work, but not anymore. People have been burned by courses and programs that didn't deliver, and they've lost trust in others and in themselves. What works now is building genuine excitement and curiosity so your audience is leaning in and asking when they can buy instead of feeling pushed into a decision. MORE FROM ME Follow me on Instagram @amyporterfield SUBSCRIBE & REVIEW If you loved this episode, please take a moment to subscribe and leave a review on Apple Podcasts! Your support helps us reach more entrepreneurs who need these insights.

Welcome to Impact Theory with Tom Bilyeu! In this eye-opening episode, Tom Bilyeu and co-host Drew tackle some of the most pressing—and controversial—headlines rocking the world this week. From Big Tech giants like Meta facing landmark lawsuits over the mental health impact of social media on kids, to explosive rumors about cancer cures being unleashed after the US's exit from the WHO, no stone is left unturned. Tom Bilyeu breaks down what's really behind these medical breakthroughs, debunking online conspiracies and explaining the critical roles of the FDA and Big Pharma. The conversation gets real about the unintended consequences of social media on developing minds, whether government intervention is the answer, and how parents can navigate the digital minefield. The hosts also deliver in-depth commentary on global power shifts, including China's economic maneuvers and Japan's political realignment, as well as the seismic advancements in AI technology that are set to reshape creative industries—and possibly life as we know it. To cap it off, Tom Bilyeu and Drew explore SpaceX's renewed focus on building a city on the moon, pondering what it means for humanity's future among the stars. Whether you're curious about the facts behind viral threads, anxious about the impact of tech on the next generation, or just want a fresh take on global headlines, this episode has something for everyone. Let's dive in! Quince: Free shipping and 365-day returns at https://quince.com/impactpodShopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impactKetone IQ: Visit https://ketone.com/IMPACT for 30% OFF your subscription orderIncogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impactBlocktrust IRA: Get up to $2,500 funding bonus to kickstart your account at https://tomcryptoira.comNetsuite: Right now, get our free business guide, Demystifying AI, at https://NetSuite.com/TheoryHuel: High-Protein Starter Kit 20% off for new customers at https://huel.com/impact code impact What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER:  https://tombilyeu.com/zero-to-founder?utm_campaign=Podcast%20Offer&utm_source=podca[%E2%80%A6]d%20end%20of%20show&utm_content=podcast%20ad%20end%20of%20show SCALING a business: see if you qualify here.:  https://tombilyeu.com/call Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here.: https://tombilyeu.com/ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Big Tech lawsuit, social media addiction, mental health, Big Pharma, cancer cures, World Health Organization (WHO), US healthcare, FDA, immunotherapy, mRNA cancer vaccines, CAR-T cell therapy, KRAS inhibitors, drug approvals, government incentives, socialism, AI breakthroughs, video AI, creative industry, China-US relations, de-dollarization, US debt, China demographics, Japan politics, sushi-fication of Japan, immigration, education policy, brain development, parental control, government regulation, space exploration, Elon Musk moon base. Learn more about your ad choices. Visit megaphone.fm/adchoices